Abstract
We describe two improved assays for in vitro and in vivo screening of inhibitors and chemicals for antimalarial activity against blood stages of the rodent malaria parasite, Plasmodium berghei. These assays are based on the determination of bioluminescence in small blood samples that is produced by reporter parasites expressing luciferase. Luciferase production increases as the parasite develops in a red blood cell and as the numbers of parasites increase during an infection. In the first assay, in vitro drug luminescence (ITDL) assay, the in vitro development of ring-stage parasites into mature schizonts in the presence and absence of candidate inhibitor(s) is quantified by measuring luciferase activity after the parasites have been allowed to mature into schizonts in culture. In the second assay, the in vivo drug luminescence (IVDL) assay, in vivo parasite growth (using a standard 4-day suppressive drug test) is quantified by measuring the luciferase activity of circulating parasites in samples of tail blood of drug-treated mice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Smilkstein M (2004) Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48:1803–1806
Baniecki ML et al (2007) High-throughput Plasmodium falciparum growth assay for malaria drug discovery. Antimicrob Agents Chemother 51:716–723
Gamo FJ et al (2010) Thousands of chemical starting points for antimalarial lead identification. Nature 465:305–310
Guiguemde WA et al (2010) Chemical genetics of Plasmodium falciparum. Nature 465:311–315
Plouffe D et al (2008) In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA 105:9059–9064
Rastu-Kapur S et al (2008) Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. Nat Chem Biol 4:203–213
Rottmann M et al (2010) Spiroindolones, a potent compound class for the treatment of malaria. Science 329:1175–1180
Franke-Fayard B et al (2008) Simple and sensitive antimalarial drug screening in vitro and in vivo using transgenic luciferase expressing Plasmodium berghei parasites. Int J Parasitol 38:1651–1662
Peters W (1987) Chemotherapy and drug resistance in malaria. Academic, London
Janse CJ, Van Vianen PH (1994) Flow cytometry in malaria detection. Methods Cell Biol 42 Pt B:295–318
Janse CJ et al (1994) Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei rodent model. Int J Parasitol 24:589–594
Sanchez BA et al (2004) Plasmodium berghei parasite transformed with green fluorescent protein for screening blood schizontocidal agents. Int J Parasitol 34:485–490
Franke-Fayard B et al (2004) A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem Parasitol 137:23–33
Spaccapelo R et al (2010) Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria. Am J Pathol 176:205–217
Janse CJ, Waters AP (1995) Plasmodium berghei: the application of cultivation and purification techniques to molecular studies of malaria parasites. Parasitol Today 11:138–143
Franke-Fayard B et al (2005) Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA 102:11468–11473
Gilks CF et al (1989) Host diet in experimental rodent malaria: a variable which can Âcompromise experimental design and interpretation. Parasitology 98(Pt 2):175–177
Chen L, Sendo F (2001) Cytokine and chemokine mRNA expression in neutrophils from CBA/NSlc mice infected with Plasmodium berghei ANKA that induces experimental cerebral malaria. Parasitol Int 50:139–143
de Souza JB, Riley EM (2002) Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect 4:291–300
Acknowledgment
Jing-wen Lin was supported by the China Scholarship Council (CSC).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Lin, Jw., Sajid, M., Ramesar, J., Khan, S.M., Janse, C.J., Franke-Fayard, B. (2012). Screening Inhibitors of P. berghei Blood Stages Using Bioluminescent Reporter Parasites. In: Ménard, R. (eds) Malaria. Methods in Molecular Biology, vol 923. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-026-7_35
Download citation
DOI: https://doi.org/10.1007/978-1-62703-026-7_35
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-025-0
Online ISBN: 978-1-62703-026-7
eBook Packages: Springer Protocols